TGF-β1: High Clinical Value and Biomedical Applications

TGF-β1 is a key immunosuppressive cytokine that regulates immune homeostasis.

It inhibits T cell proliferation and differentiation, suppresses natural killer (NK) cell activity, and promotes the generation of regulatory T cells (Tregs).

These functions are critical for maintaining immune tolerance and preventing autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis.

TGF-β1 plays a dual role in cancer biology.

In early stages, it can suppress tumor growth; however, during tumor progression, it promotes metastasis and invasion.

Within the tumor microenvironment, TGF-β1 induces epithelial–mesenchymal transition (EMT), enhances cell migration, and facilitates immune evasion.

As a result, TGF-β1 signaling pathways have become key targets for anticancer drug development, particularly for metastatic cancers.

TGF-β1 is a major driver of fibrosis across multiple organs.

It stimulates fibroblast proliferation and extracellular matrix deposition, leading to tissue scarring and organ dysfunction.

This mechanism is implicated in pulmonary, hepatic, renal, and cardiac fibrosis.

Targeting TGF-β1 signaling is a promising strategy for developing antifibrotic therapies.

TGF-β1 plays a central role in wound healing and tissue regeneration.

It promotes extracellular matrix remodeling and fibroblast differentiation, accelerating tissue repair.

In regenerative medicine, TGF-β1 is used in biomaterials and tissue engineering to enhance repair efficiency.

It is also widely studied in cartilage and bone regeneration, particularly in conditions such as osteoarthritis and fracture healing.

TGF-β1 is closely associated with cardiovascular pathologies, including cardiac hypertrophy, myocardial fibrosis, and atherosclerosis.

Modulating TGF-β1 signaling may help prevent pathological remodeling and improve outcomes in heart failure and coronary artery disease.

Several TGF-β1-targeted therapies are currently under preclinical and clinical investigation.

TGF-β1 exhibits anti-inflammatory properties by suppressing pro-inflammatory cytokine production.

It also regulates host immune responses during infections, playing a role in chronic viral and bacterial disease progression.

Targeting TGF-β1 pathways may offer new strategies for controlling chronic inflammation and infectious diseases.

TGF-β1 is a central regulator in both physiological and pathological processes.

Its diverse functions across immunity, fibrosis, cancer, and tissue repair make it a highly valuable target in both basic research and clinical applications.

Ongoing studies continue to uncover new therapeutic opportunities based on TGF-β1 signaling modulation.